Treatment of unresectable stage IV metastatic melanoma with aviscumine after anti-neoplastic treatment failure: a phase II, multi-centre study.

Jacalin-Activated Macrophages Exhibit an Antitumor Phenotype. Biomed Res Int (2016) 0.75

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74

Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22

Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34

Mutations of the BRAF gene in human cancer. Nature (2002) 65.42

Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11

Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08

Optimal two-stage designs for phase II clinical trials. Control Clin Trials (1989) 21.03

Distinct sets of genetic alterations in melanoma. N Engl J Med (2005) 17.26

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 13.89

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol (2009) 8.68

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol (2008) 8.09

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol (2006) 7.33

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44

Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med (1999) 6.09

A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res (2009) 5.99

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol (1999) 5.95

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol (2010) 5.91

Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst (2010) 5.23

Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol (2004) 3.97

Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. Cancer Invest (2008) 3.69

Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol (2006) 2.88

Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. Cancer (2010) 2.73

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol (2012) 2.45

Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol (2002) 1.98

Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin Cancer Res (2006) 1.53

Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. Cochrane Database Syst Rev (2007) 1.43

Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. Ann Oncol (2006) 1.29

Surface alpha 2-3- and alpha 2-6-sialylation of human monocytes and derived dendritic cells and its influence on endocytosis. Glycoconj J (2007) 1.19

Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. J Clin Oncol (1990) 1.17

Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial. Cancer Immunol Immunother (2012) 1.08

Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients. Melanoma Res (2001) 1.06

Immunotherapy for advanced melanoma. J Invest Dermatol (2008) 1.05

Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438). Clin Cancer Res (2012) 1.04

Regression in skin tumours: a common phenomenon. Australas J Dermatol (1997) 1.01

Beta-galactoside alpha2,6 sialyltransferase in human colon cancer: contribution of multiple transcripts to regulation of enzyme activity and reactivity with Sambucus nigra agglutinin. Int J Cancer (2000) 0.98

Increased alpha2,6-sialylation of surface proteins on tolerogenic, immature dendritic cells and regulatory T cells. Exp Hematol (2006) 0.98

Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. Cancer J Sci Am (1997) 0.96

Characterization of recombinant and plant-derived mistletoe lectin and their B-chains. Eur J Biochem (1999) 0.95

Murine B cell differentiation is accompanied by programmed expression of multiple novel beta-galactoside alpha2, 6-sialyltransferase mRNA forms. Glycobiology (2000) 0.92

Effect of a recombinant lectin, Viscum album agglutinin on the secretion of interleukin-12 in cultured human peripheral blood mononuclear cells and on NK-cell-mediated cytotoxicity of rat splenocytes in vitro and in vivo. Nat Immun (1998) 0.91

Clinicopathologic evaluation of CDw75 antigen expression in colorectal adenocarcinomas. Pathol Oncol Res (2003) 0.85

Phase I trial of r viscumin (INN: aviscumine) given subcutaneously in patients with advanced cancer: a study of the European Organisation for Research and Treatment of Cancer (EORTC protocol number 13001). Eur J Cancer (2008) 0.84

Cloning of the mistletoe lectin gene and characterization of the recombinant A-chain. Eur J Biochem (1999) 0.83

Site-specific mutagenesis of mistletoe lectin: the role of RIP activity in apoptosis. Biochem Biophys Res Commun (1999) 0.83

Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group. Eur J Cancer (2006) 0.82

Preferential binding of the anticancer drug rViscumin (recombinant mistletoe lectin) to terminally alpha2-6-sialylated neolacto-series gangliosides. Glycobiology (2002) 0.82

Anticancer activity of rViscumin (recombinant mistletoe lectin) in tumor colonization models with immunocompetent mice. Anticancer Res (2002) 0.81

Recombinant interleukin-2. Pharmacotherapy (1995) 0.80

Using benchmarks based on historical survival rates for screening new therapies for stage IV melanoma patients. J Clin Oncol (2008) 0.79

Clinical use of biologic response modifiers in cancer treatment: an overview. Part II. Colony-stimulating factors and interleukin-2. DICP (1991) 0.78

CD75s is a marker of murine CD8(+) suppressor T cells. Int Immunol (2003) 0.77

Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol (2015) 1.90

The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. J Am Acad Dermatol (2016) 0.84

Remission of an intracardiac melanoma metastasis after tremelimumab therapy. Case Rep Dermatol (2014) 0.75